Eric Mou

Lymphoma Doctor at the University of Iowa | Residency and Fellowship, Stanford | MD, University of Iowa | Childhood, Iowa

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh]

I used to be a vocal skeptic of Hans and a key GEP fan, some say as an OG for GEP. I used to lament Hans IHC as the only tool available for my patients, when many trials used GEP instead.

But I have been surprised by learning how IHC has dramatically improved over the last decade or so with availability of standardized antibody clones, use of auto strainers, and interpretation consistency.

How was I convinced?

We did a systematic meta-analysis of >2200 patients from 19 studies. We used the PRISMA diagnostic test accuracy framework for comparing Hans to GEP.

https://t.co/qHJvtE7aFQ

Remarkably, this analysis now clearly shows that Hans is consistently non-inferior to GEP across current modern studies at a 10% NI margin for Accuracy, Precision, and Specificity.

This solid performance of Hans IHC is very much in line with current CAP benchmarks for diagnostic tests, and within the margins of NanoString GEP using FFPE vs original frozen GEP as the original elusive gold standard.

Long live Hans as the best currently available SOC for COO across the globe.

[NCAA March Madness @MarchMadnessMBB]

ARE. YOU. JOKING.

IOWA LEADS. THIS IS MARCH. #MarchMadness

[Vijay Sankaran @bloodgenes]

If you have not read this moving and courageous essay from Tatiana Schlossberg in the @NewYorker, please check it out. You may be wondering why inv(3) leukemia is so deadly? Here is a brief 🧵 (1/n)

[Udhayvir Grewal @UGrewalMD]

Three years and tons of memories. I’m going to miss these guys. @UIowaCancer heme onc fellowship class of 2025!

[Toby Eyre @tobyeyre82]

Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology https://t.co/JyptYBMh78

[Michael Sargent Binkley @michaelsbinkley]

Grateful to have the opportunity to write this editorial on current management of classic Hodgkin lymphoma with Dr. Ranjana Advani https://t.co/SxX5VayMsM

[Jan Jensen @goiowa]

On behalf of @avajones_35 & her family, we thank all for your continued support as Ava takes on another battle & begins treatment for cancer. For those who have inquired, plz send cards to our @IowaWBB office. Your thoughts & prayers are also so appreciated. 🙏🏼God bless.

[SSN Jay-O @Jay_3shifty]

Hawkeye fans and WBB fans let’s all do what we can to help Ava Jones!!
https://t.co/9EjpNIluQ7

[Eric Mou @emouMD]

@MediHumdani Option 2. Impact of ABVD on fertility is known to be low; (emerging) data suggests nivo-AVD is similarly safe:

https://t.co/Hht8xcJgwP

[Hira Shaikh @hiragss]

Proud mentor of @mehndz presenting our #MGRS data at #ASH24 as poster tonight.
-> Hematological ≥VGPR to induction significantly affecting TTNT (HR 0.07, p<0.001) on univariate and multivariate.
-> Novel therapies, including anti-CD38 had + outcomes, results not SS.

[Cody Hills @ByCodyHills]

At his weekly presser today, Kirk Ferentz was asked how he formulates relationships with @UIchildrens Kid Captains & their families.

He gave a 3-minute answer, but this particular perspective right here is special.

Not many college football coaches have this in them. #Hawkeyes

[Eric Mou @emouMD]

@dgermain21 I agree, QoL analysis is critical in my opinion. irAEs are a unique set of toxicities; is ICI-induced hypothyroidism, which consigns many (often AYA pts) to require a new, lifelong, daily medication truly “non-serious” as would be concluded in a standard safety analysis?

[UI Holden Comprehensive Cancer Center @UIowaCancer]

Feeling nostalgic this morning as Director Emeritus Dr. George Weiner proudly holds the official letter that first declared us a 'comprehensive' cancer center by @theNCI. As we approach 25 years, we reflect on the incredible strides the center has made!

[Michael Sargent Binkley @michaelsbinkley]

Monumental effort by GLOW team in publishing the largest analysis of NLPHL to date and answering many key questions about age specific risks, the prognostic impact of variant patterns, and developing a new LP-IPS: https://t.co/kuGpmIMEsh @glow_nlphl @JCO_ASCO @JamieFlerlage

[Eric Mou @emouMD]

@Eric_Reynoldsmd Memories…

[Eric Mou @emouMD]

Drove home from work today through gridlock traffic surrounding the arena, hours before tipoff. Just an unreal scene.

[Iowa Women's Basketball @IowaWBB]

THE shot.

@caitlinclark22 x #Hawkeyes

[Jay Daniels @jay_daniels1]

excited to share work from my PhD in @jaehyukchoimd's lab, out today in @Nature. in collaboration with @KoleRoybal and @jcole_garcia, we leveraged mutations evolved in human T cells to empower anti-cancer T cells https://t.co/nbmp853S16

[Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh]

Thrilled to share our new study describing distinct subtypes of #HodgkinLymphoma #cHL out today @Nature. #lymsm 1/15
https://t.co/FOBvWSu5Je PDF link at bottom of this thread

[Andrew M. Evens, DO, MBA, MSc @DrAEvens]

🙌 Great #HoLISTIC consortium meeting today (https://t.co/DgIpQkVl7V)!

We look forward to presentations at @ASH_hematology (below) & the many ongoing & planned HL projects.

https://t.co/V7Y5PeOtcp

https://t.co/JZCNGDOUEZ

https://t.co/BxHKRAMTKq

#ASH23 #dataanalytics #bigdata